

Corrections to Heat Shock Protein 90: Inhibitors in Clinical Trials [*J. Med. Chem.* 2010, 53, 3. DOI: 10.1021/jm9004708]. Marco A. Biamonte,* Ryan Van de Water, Joseph W. Arndt, Robert H. Scannevin, Daniel Perret, and Wen-Cherng Lee

Page 6. Section 3.5 incorrectly states that “Vernalis screened for compounds able to bind HSP90 and identified as a starting point resorcinol **19** [CCT018159] ...”. The HSP90 inhibitor CCT018159 was originally discovered by high-throughput screening at the Centre for Cancer Therapeutics, hence the CCT nomenclature (ref 91). The CCT is located within The Institute for Cancer Research, a college of the University of London, which subsequently entered into a collaborative discovery program with Vernalis, culminating in the resorcinol **7** in clinical trials. We feel it is important to give due credit to the CCT/ICR contribution to the discovery of **7**, since the relationship between academia and industry is key in developing new drugs.

DOI: 10.1021/jm100114u
Published on Web 02/10/2010